Opinion|Videos|September 15, 2023
Common Testing Strategies for Molecular Markers in mCRC
Experts emphasize the importance of acquiring both tissue and circulating tumor DNA (ctDNA) for molecular testing in patients with metastatic colorectal cancer, address challenges such as lack of tissue and costs, and highlight the role of HER2 as a biomarker.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
3
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5